Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Moderate-to-Severe Acne: Comparison of 4 Clinical Trials

Leah H Kircik, MD; Zoe D Draelos, MD; Michael Gold, MD; Neil Sadick, MD; Neel Bhatia, MD

Study Methods and Results

CONCLUSIONS

CAB gel—the first and only fixed-dose, triple-combination topical treatment approved for acne—consistently demonstrated efficacy, safety, and tolerability in participants with moderate-to-severe acne.

In 4 clinical trials, half of CAB-treated participants achieved treatment success at week 12, significantly greater than the approximately one third with dyad combinations (including branded ADAP/BPO 0.3%/2.5% gel) or vehicle gel. Triplet-combination CAB gel had the lowest (most favorable) NNT values.

Due to the multifactorial pathogenesis of acne, a triple-combination topical treatment may result in clinical success more often than monotherapy or two-ingredient combination products.